Supplementary Files
Keywords
Chronic inflammatory skin disease
Immunoglobulin E
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory and complex skin disease, typically occurring in individuals with a personal or family history of atopy. It is characterized by lesions of dermatitis, pruritus and dry skin (xerosis) that evolve with chronic course and intermittent outbreaks alternating with remission phases. AD appears from 5-15 % of the general population, 10-20 % of the pediatric population, and 1-3 % of the adult population.
Case report: A 19-year-old male patient with a severe AD (SCORAD of 84.3), and hyper-IgE (34 400 UI/mL), who was treated with deflazacort, Healing creams and emollients, as well as detergent-free gel. With which did not progress favorably, so a combinated therapy with deflazacort, methotrexate, tacrolimus, and transfer factor was prescribed, obtaining excellent results.
Conclusion: There are many algorithms reported in the literature for the treatment of AD, but the evolution of the disease is the only one that will give us the guidelines for the treatment to be followed.
References
Del-Pino-Rivero-Suárez M, Carretero-Hernández G. Estudio clínico y alergológico en pacientes con manifestaciones cutáneas minor de dermatitis atópica. Actas Dermosifiliogr. 2002;93(4):231-242. DOI: http://dx.doi.org/10.1016/S0001-7310(02)76564-2
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venerol Suppl (Stockh). 1980;92(1):44-47. DOI: http://dx.doi.org/10.2340/00015555924447
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336-349. DOI: http://dx.doi.org/10.1016/j.jaci.2016.06.010
Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dematitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76. DOI: http://dx.doi.org/10.1016/j.jaci.2017.01.011
Staines-Boone AT, Piña-Osuna AK, Amaya-Guerra M, García-Campos JA, Reyes-Delgado K. Dermatitis atópica resistente en tratamiento con omalizumab. Dermatol Rev Mex. 2013;57(1):192-195. Disponible en: http://www.medigraphic.com/pdfs/derrevmex/rmd-2013/rmd133j.pdf
Pueyo TS, García MA, García-Díaz R, Castro C. Consenso Nacional de Dermatitis Atópica. Argentina: Sociedad Argentina de Dermatología; 2004.
Bieber T, Novak N. New concepts of atopic dermatitis: From non-IgE-mediated via IgE-mediated to autoimmune inflammation. Allergy Clin Immunol Int. 2005;17(1):26-29.
Arévalo-Jaramillo MD, Sánchez-Vaca F. Determinación serológica de IgE en pacientes con diagnóstico clínico de dermatitis atópica en el centro de la piel (CEPI) y su correlación con la gravedad evaluada con SCORAD y escala CEPI en el momento de toma de la muestra en el periodo de mayo a octubre de 2014. Tesis de licenciatura. Quito, Ecuador: Pontificia Universidad Católica del Ecuador; 2014. p. 95.
Yashapour M, Agarwal S, Jerome D, Yel L. Is it hyper IgE syndrome or something else? MOJ Immunol. 2004;1(2):1-4. Disponible en: http://medcraveonline.com/MOJI/MOJI-01-00010.pdf
El Médico Interactivo [Sitio web]. Guerra-Tapia A. González G, E. Dermatitis atópica. Disponible en: http://2011.elmedicointeractivo.com/Documentos/doc/dermatitis.pdf
Sendagorta-Cudós E, De-Lucas-Laguna R. Tratamiento de la dermatitis atópica. Rev Pediatr Aten Primaria. 2009;11(15):49-67. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1139-76322009000300004
Laguna-Argente C, Vilata-Corell JJ. Dermatitis atópica del adulto. Med Cutan Iber Lat Am. 2006;34(1):5-10. Disponible en: http://www.medcutan-ila.org/images%5Cpdf/articulos/2006/1/pdf/05-095.pdf
Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of metrotexate versus azatioprine for severe atopic eczema. J Allergy Clin Inmunol. 2011;128(2):353-359. DOI: http://dx.doi.org/10.1016/j.jaci.2011.03.024
Arjona-Aguilera C, Albarrán-Planelles, Tercedor-Sánchez J. Trastornos genéticos con eccema moderado-grave refractario y elevación de inmunoglobulina E: diagnóstico diferencial. Actas Dermosifiliogr. 2016;107(2):116-124. DOI: http://dx.doi.org/10.1016/j.ad.2015.09.013
Hahn BH, Pletscher LS, Muniain M. Inmmunosuppressive effects of deflazacort-a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: Comparison with prednisone. J Rheumatol. 1981;8(5): 783-790.
Kim JE, Kim HJ, Lew BL, Lee KH, Hong SP, Jang YH, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (Part II): Systemic treatment. Ann Dermatol. 2015;(27)5:578-592. DOI: http://dx.doi.org/10.5021/ad.2015.27.5.578
Garnacho-Saucedo G, Salido-Vallejo R. Actualización de dermatitis atópica. Propuesta de algoritmo de actualización. Actas Dermosifiligr. 2013;104(1):4-16. DOI: http://dx.doi.org/10.1016/j.ad.2011.12.008
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139. DOI: http://dx.doi.org/10.1056/NEJMoa1314768
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2017 Revista Alergia México